eligibility_summary
Adults 18–80 with asthma per GINA (reversibility ≥12% and ≥200 mL or positive methacholine), ± nasal polyps, already in MEGA, consent. Biologics cohort: uncontrolled asthma on medium–high ICS+2nd controller ≥3 mo, FEV1<80% or FEV1/FVC<70, ACQ-5≥1.5 or ACT<19 and/or recent exacerbation, biologic per biomarkers, IgE 75–1500 for omalizumab (Spanish rules). Already in biologics cohort. Exclude COPD/other lung disease, interfering comorbidity, other trials, or lack capacity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational Spanish registry following adults with asthma (± nasal polyposis) receiving real‑life antiasthmatic therapy, especially biologics. Interventions/drugs: monoclonal antibody biologics used per routine care—dupilumab (anti–IL‑4Rα, blocks IL‑4/IL‑13 signaling), mepolizumab and reslizumab (anti–IL‑5, reduce eosinophil maturation/survival), benralizumab (anti–IL‑5Rα, depletes eosinophils via ADCC), omalizumab (anti‑IgE, lowers free IgE and FcεRI activation on mast cells/basophils). Other controllers (e.g., ICS/LABA/LTRA) per clinician judgment. Cells/pathways targeted: Type 2 inflammation—IL‑4/IL‑13 axis, IL‑5/IL‑5R, IgE/FcεRI, primary cellular targets are eosinophils (including depletion with benralizumab), mast cells and basophils (via IgE blockade). The registry also profiles T2 biomarkers and upstream/alarm pathways (TSLP, IL‑33, IL‑25), IL‑6, FeNO, periostin, and eosinophil subsets by single‑cell analyses.